RNA Ribozyme Therapy RZ-001 Shows Strong Early Response Rates in Liver Cancer Trial
Interim data from AACR 2026 show RZ-001 combo therapy achieved up to 61.5% response rate in hard-to-treat liver cancer patients.
Summary
A novel RNA-based therapy called RZ-001, combined with immunotherapy drugs atezolizumab and bevacizumab, showed promising early results in patients with hepatocellular carcinoma — the most common form of liver cancer. Presented at the AACR 2026 conference, the interim data reported confirmed objective response rates of 38.5% and up to 61.5% using a more sensitive measurement standard. Notably, nearly one in four patients achieved a complete response. The therapy appeared safe, with no serious adverse events directly linked to RZ-001 itself. These results support continued development of the RNA trans-splicing ribozyme platform, a cutting-edge genetic medicine approach that could expand treatment options for liver cancer patients who have failed or cannot undergo standard local therapies.
Detailed Summary
Hepatocellular carcinoma, or HCC, is the most prevalent form of primary liver cancer and one of the leading causes of cancer-related death worldwide. It is notoriously difficult to treat, especially in patients who cannot undergo or have stopped responding to standard local procedures like transarterial chemoembolization. New therapeutic approaches are urgently needed for this population.
At the American Association for Cancer Research annual meeting in April 2026, biotech company Rznomics presented interim clinical data for its experimental therapy RZ-001. When combined with the immunotherapy drugs atezolizumab and bevacizumab — already an approved first-line HCC regimen — RZ-001 produced a confirmed objective response rate of 38.5% and an unconfirmed rate of 46.2% by standard RECIST v1.1 criteria. Using the more tumor-specific mRECIST criteria, the objective response rate climbed to 61.5%, with a complete response rate of 23%.
RZ-001 is built on an RNA trans-splicing ribozyme platform, a sophisticated genetic medicine technology that reprograms cancer-related RNA transcripts. This approach is distinct from conventional chemotherapy or even most immunotherapies, representing a new class of nucleic acid-based cancer treatment with potential applications beyond HCC.
Safety data were encouraging. Five Grade 3 or higher adverse events were recorded, but all were attributed to the combination partner drugs — hypertension, proteinuria, hyperglycemia, and gastrointestinal bleeding — not to RZ-001 itself. No serious adverse events were linked directly to the experimental agent.
While these results are preliminary and drawn from a small patient cohort, the response rates and safety profile are notable for a refractory HCC population. Larger, controlled trials will be needed to confirm efficacy and establish RZ-001's role in the treatment landscape. For longevity-focused readers, advances in liver cancer treatment directly impact healthspan and survival in a disease with rising global incidence.
Key Findings
- RZ-001 combo achieved a 61.5% objective response rate by mRECIST criteria in refractory liver cancer patients.
- Complete response rate of 23% was observed, meaning nearly 1 in 4 patients showed full tumor regression by mRECIST.
- No Grade 3 or higher adverse events were directly attributed to RZ-001, suggesting a favorable safety profile.
- RZ-001 uses an RNA trans-splicing ribozyme platform, a novel genetic medicine approach distinct from standard therapies.
- Results support further clinical development of RZ-001 in combination with approved immunotherapy agents for HCC.
Methodology
This is a news report summarizing interim clinical trial data presented at AACR 2026, a major peer-reviewed oncology conference. The source, Longevity.Technology, is a credible health and longevity media outlet; however, the data originate from the sponsoring company Rznomics and have not yet been published in a peer-reviewed journal. Evidence basis is interim clinical data, not a completed randomized controlled trial.
Study Limitations
Data are interim and from a small cohort, limiting statistical power and generalizability. Results were presented by the sponsoring company and have not yet undergone independent peer review or journal publication. Response rates may shift as more patients are enrolled and followed over longer periods.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.